Business Economy


Shriram Life Individual NBP up 21 pc in Q1

Chennai, Aug 6 (UNI)Shriram Life Insurance Company Ltd reported a 21% year-on-year growth
in Individual New Business Premium (NBP) in the first quarter of fiscal 2026, driven by a broader distribution footprint, higher average ticket size, and branch expansion.
The NBP grew from Rs 212 crore in Q1FY25 to Rs 257 crore in Q1FY26.
For Q1FY26, the average ticket size, or the average premium amount per policy sold, for individual policies stands at Rs 24,799. It was Rs 15,192 in Q1FY25. In comparison, the average ticket size for the private industry for Q1FY26 is Rs 87,373.
This growth in average ticket size is also reflected in the Individual New Business APE (Annualized Premium Equivalent), which rose 9% year-on-year to Rs 215 crore in Q1FY26, up from Rs 198 crore in Q1FY25, a company statement here said.
Renewal premium across individual business rose by 25% year-on-year, reaching Rs 323 crore
in Q1FY26 from Rs 259 crore in Q1FY25. Total premium for Q1FY26 rose 27% year-on-year to
Rs 863 crore from Rs 679 crore.
SLIC’s Assets Under Management (AUM) grew 17% to Rs 13,799 crore in Q1FY26 from Rs 11,841 crore in Q1FY25. The company sold 86,750 policies in Q1FY26. The solvency ratio for the quarter stands at 1.75.
Casparus J.H. Kromhout, MD and CEO, said, “Shriram Life Insurance is guided by a clear vision — to deepen its presence in rural and semi-urban markets and reach every corner of the country. Our strategy is focussed on making life insurance simpler and more accessible for everybody we serve.”
During the first quarter of FY26, the company settled 18,023 claims in both individual and group policies compared with 15,924 claims in the same period last fiscal. In FY25, the company settled 98.31% of individual claims, with 93% of all non-investigated claims settled within 12 hours of receiving the last document.
SLIC has been systematically deepening strategic partnerships to broaden its reach into the remotest corners of the country and reinforcing its commitment to financial inclusion.
"We believe protection should not be a privilege, but a basic financial right for every Indian household — no matter where they live or what they earn. That’s why these partnerships matter," said Kromhout.
UNI GV 1745
More News

Telangana Govt initiates expansion plan for nine new Singareni mining projects

10 May 2026 | 12:01 AM

Hyderabad, May 9 (UNI) The Telangana Government has initiated a comprehensive expansion plan for development of nine new mining projects for Singareni Collieries Company Limited (SCCL) to ensure long-term energy security, sustain coal production and protect employment opportunities.

see more..

Dr Hemant Sharad Pande assumes charge as WCL CMD

09 May 2026 | 10:03 PM

Nagpur, May 9 (UNI) Dr. Hemant Sharad Pande on Friday assumed charge as Chairman-cum-Managing Director (CMD) of Western Coalfields Limited (WCL), the company said in a press release issued here on Saturday.

see more..

L&T bags Rs 2,500 cr coal-to-ammonium nitrate plant order

09 May 2026 | 6:29 PM

Mumbai, May 9 (UNI) Larsen & Toubro (L&T) Ltd has officially announced to the stock exchange through a regulatory filing that its energy hydrocarbon onshore business has secured an engineering, procurement and construction (EPC) order from Bharat Coal Gasification and Chemicals Ltd (BCGCL), for a coal-to-ammonium nitrate fertiliser project in Odisha.

see more..

PHDCCI welcomes Rs 5,000 cr ECLGS package for airlines amid West Asia crisis

09 May 2026 | 3:51 PM

New Delhi, May 9 (UNI) The PHD Chamber of Commerce and Industry (PHDCCI) welcomed the government's decision to approve a Rs 5,000 crore emergency credit support scheme for airlines under ECLGS 5.0 to address the financial and operational stress arising from the ongoing West Asia crisis.

see more..

Dr Reddy’s–Nestlé Health Science JV launches Celevida GLP for patients on obesity, diabetes therapies

09 May 2026 | 12:30 AM

Hyderabad, May 8 (UNI) Dr. Reddy’s Laboratories and Nestlé India on Friday announced the launch of ‘Celevida GLP ’, a specialised nutritional product designed to support muscle mass maintenance and nutritional needs of people undergoing GLP-1/GIP therapy for management of type 2 diabetes and obesity in India.

see more..